Qiagen N.V. $QGEN Shares Sold by Amundi

Amundi reduced its position in Qiagen N.V. (NYSE:QGEN) by 5.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 4,108,764 shares of the company’s stock after selling 244,970 shares during the period. Amundi owned about 1.85% of Qiagen worth $199,850,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. SVB Wealth LLC purchased a new stake in shares of Qiagen in the first quarter valued at $31,000. MAI Capital Management boosted its stake in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after buying an additional 849 shares during the period. Allworth Financial LP grew its holdings in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after buying an additional 796 shares during the period. Finally, Cullen Frost Bankers Inc. increased its stake in shares of Qiagen by 13,144.4% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after acquiring an additional 1,183 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

QGEN has been the topic of several research analyst reports. Barclays set a $53.00 target price on shares of Qiagen and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 1st. Three equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $49.69.

Qiagen Price Performance

Qiagen stock opened at $47.04 on Friday. The firm has a fifty day moving average of $46.51 and a 200-day moving average of $47.00. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $10.46 billion, a P/E ratio of 25.57, a PEG ratio of 2.40 and a beta of 0.68.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, November 6th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. During the same quarter in the previous year, the business posted $0.57 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.